Radensky P W, Hilton T C, Fulmer H, McLaughlin B A, Stowers S A
Health Law Department, McDermott, Will and Emery, Miami, Florida 33131, USA.
Am J Cardiol. 1997 Mar 1;79(5):595-9. doi: 10.1016/s0002-9149(96)00822-3.
Previous investigations have confirmed the diagnostic and predictive usefulness of initial single-photon emission computed tomography (SPECT) myocardial perfusion imaging using technetium-99m sestamibi in the evaluation of emergency department patients with chest pain. Patients with a normal SPECT perfusion scan performed during chest pain have an excellent short-term prognosis, and may be candidates for expeditious cardiac evaluation or outpatient management. However, there are limited data regarding the cost effectiveness of this technique. This analysis models the potential cost effectiveness of this procedure. In the current investigation we compared 2 model strategies for management of emergency department patients with typical chest pain and a normal or nondiagnostic electrocardiogram (ECG). In 1 model strategy, (the technetium-99m sestamibi SPECT myocardial perfusion imaging [SCAN] strategy), the decision whether to admit or discharge a patient from the emergency department is based on results of initial technetium-99m sestamibi SPECT myocardial imaging. Patients with normal scans are discharged; others are admitted. In the second model strategy, (the NO SCAN strategy), the decision whether or not to admit a patient is based on a combination of clinical and electrocardiographic variables. Patients with > or = 3 cardiac risk factors or an abnormal ECG are admitted; others are discharged. Adverse cardiac events were prospectively defined as cardiac death, nonfatal myocardial infarction, or the need for acute coronary intervention. Costs were assigned using data derived from 102 patients who underwent SPECT myocardial perfusion imaging and an additional 107 emergency department patients with ongoing chest pain who either underwent or were eligible for initial SPECT myocardial perfusion imaging. Mean (+/- SE) costs were highest among hospital admitted patients who experienced an adverse cardiac event ($21,375 +/- $2,733) and lowest in patients discharged from the emergency department ($715 +/- 71). Mean costs per patient of the SCAN strategy and NO SCAN strategy were $5,019 versus $6,051, respectively. These results were stable in a sensitivity analysis across a range of costs and predictive values. Thus, the SCAN model strategy for initial management of emergency department patients with typical ongoing angina and a normal or nondiagnostic ECG using initial myocardial perfusion imaging with technetium-99m sestamibi appears to be safe, accurate, and potentially cost effective. Validation of these preliminary retrospective observations will require further prospective investigation.
以往的研究已证实,在评估急诊科胸痛患者时,使用锝-99m 甲氧基异丁基异腈进行初始单光子发射计算机断层扫描(SPECT)心肌灌注成像具有诊断和预测价值。胸痛发作时 SPECT 灌注扫描正常的患者短期预后良好,可能适合快速心脏评估或门诊治疗。然而,关于该技术成本效益的数据有限。本分析对该检查的潜在成本效益进行了建模。在当前研究中,我们比较了两种用于管理急诊科典型胸痛且心电图(ECG)正常或无诊断意义的患者的模型策略。在一种模型策略中,(锝-99m 甲氧基异丁基异腈 SPECT 心肌灌注成像[SCAN]策略),决定患者是从急诊科入院还是出院基于初始锝-99m 甲氧基异丁基异腈 SPECT 心肌成像结果。扫描正常的患者出院;其他患者入院。在第二种模型策略中,(无扫描策略),决定是否收治患者基于临床和心电图变量的综合情况。有≥3 个心脏危险因素或心电图异常的患者入院;其他患者出院。不良心脏事件被前瞻性定义为心源性死亡、非致命性心肌梗死或需要急性冠状动脉介入治疗。成本分配使用了来自 102 例接受 SPECT 心肌灌注成像的患者以及另外 107 例急诊科持续胸痛且已接受或有资格接受初始 SPECT 心肌灌注成像的患者的数据。平均(±SE)成本在发生不良心脏事件的住院患者中最高(21,375 美元±2,733 美元),在从急诊科出院的患者中最低(715 美元±71 美元)。SCAN 策略和无扫描策略的每位患者平均成本分别为 5,019 美元和 6,051 美元。在一系列成本和预测值的敏感性分析中,这些结果是稳定的。因此,使用锝-99m 甲氧基异丁基异腈进行初始心肌灌注成像对急诊科典型持续性心绞痛且心电图正常或无诊断意义的患者进行初始管理的 SCAN 模型策略似乎是安全、准确且可能具有成本效益的。对这些初步回顾性观察结果的验证需要进一步的前瞻性研究。